Janssen Therapeutics's Prezista 800 Mg Tablet Receives FDA Approval
Published: Nov 12, 2012
Janssen Therapeutics, division of Janssen Products, LP, has received the US Food and Drug Administration (FDA) approval for a new 800mg tablet of Prezista (darunavir) for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations. Prezista is always taken with and at the same time as ritonavir with food and in combination with other HIV medicines. The new tablet strength will allow patients taking Prezista once daily to reduce the number of Prezista tablets by half, taking one 800mg tablet instead of two 400mg tablets once a day with ritonavir 100mg and other antiretroviral medications.